Advances in the Proteomic Discovery of Novel Therapeutic Targets in Cancer
National Institutes of Health/National Institute on Minority and Health Disparities, Louisiana Cancer Research Consortium, Department of Agriculture, Office of Naval Research
8G12MD007590 (JZ), 3G12MD007595 (GW), 58-6435-7-019 (GW), N00014-99-1-0763 (GW)
Department of Chemistry
Proteomic approaches are continuing to make headways in cancer research by helping to elucidate complex signaling networks that underlie tumorigenesis and disease progression. This review describes recent advances made in the proteomic discovery of drug targets for therapeutic development. A variety of technical and methodological advances are overviewed with a critical assessment of challenges and potentials. A number of potential drug targets, such as baculoviral inhibitor of apoptosis protein repeat-containing protein 6, macrophage inhibitory cytokine 1, phosphoglycerate mutase 1, prohibitin 1, fascin, and pyruvate kinase isozyme 2 were identified in the proteomic analysis of drug-resistant cancer cells, drug action, and differential disease state tissues. Future directions for proteomics-based target identification and validation to be more translation efficient are also discussed.
Guo, S.; Zou, J.; and Wang, Guangdi, "Advances in the Proteomic Discovery of Novel Therapeutic Targets in Cancer" (2013). Faculty and Staff Publications. 142.